Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including astrocytes; strongest in bergmann glia | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 19 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 12161
Sealed predictions
- SFXN5 in astrocytes, braak+0.18 (p 0.635) → -0.42 (p 0.258)receipt 12168
- SFXN5 in dopamine neurons, braak-0.85 (p 0.004) → -0.10 (p 0.802)receipt 12169
Swarm cases
receipt 12169: SFXN5 in dopamine neurons, braak
- power
- full sample -0.43 (p 0.077, n 18), 95% CI -0.75 to +0.05. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.40 (p 0.099, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.56 (p 0.015, n 18). not the mix.
- skeptic
- leave-one-out range -0.51 to -0.35, sign flips 0; without severely affected donors -0.43 (p 0.077, n 18). robust.
- cell type
- strongest in oligodendrocytes: -0.66 (p 0.0028, n 18) vs -0.43 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SFXN5 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SFXN5 · oligodendrocytes · braak: substantia nigra, an independent cohort (already registered)
receipt 12168: SFXN5 in astrocytes, braak
- power
- full sample -0.12 (p 0.627, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.09 (p 0.735, n 18). does not hold up.
- composition
- astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.03 (p 0.908, n 18). could be the mix.
- skeptic
- leave-one-out range -0.23 to +0.00, sign flips 1; without severely affected donors -0.12 (p 0.627, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.66 (p 0.0028, n 18) vs -0.12 in astrocytes. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SFXN5 in astrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SFXN5 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.43 p 0.131 (needs p < 1.8e-4)
Receipts
loading the receipts